From: EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Demographic characteristics
Everolimus
N  =  120
Age, median (range), years
11.0 (1–47) a
Sex, n (%)
 Male
62 (51.7)
 Female
58 (48.3)
Race, n (%)
 Caucasian
116 (96.7)
 Asian
2 (1.7)
 Native American
1 (0.8)
 Other